

**ASX Announcement | 26 October 2023
Vioneering Technologies (ASX:VTI)**

Extension of Closing Date for Rights Offering

Vioneering Technologies, Inc. (ASX: VTI) ('**Vioneering**' or 'the **Company**'), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, advises that the closing date for its 5 for 9 non-renounceable pro rata non-renounceable rights offering announced to ASX on 10 October 2023 (**Rights Offering**) has been extended by one week to Monday, 6 November 2023. The updated timetable for the remaining dates is as follows:

Event	Date
Rights Offering closes	5:00pm, Monday, 6 November 2023
Announce results to ASX	By Monday, 13 November 2023
Issue of CDIs under Rights Offering and Placement, conversion of Convertible Notes to CDIs	Monday, 13 November 2023
CDIs under Rights Offering commence trading on ASX on a normal basis	Tuesday, 14 November 2023
Dispatch of holding statements	Thursday, 16 November 2023

Note: The timetable above may be varied subject to the Listing Rules. All times are references to Sydney time.

Enquiries

Further details about the Rights Offering are set out in the Offer Booklet. Eligible Holders should read the Offer Booklet carefully before making any investment decision regarding the Rights Offering.

For further information regarding the Rights Offering, please call the Rights Offering Information Line on 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) between 8.30am and 5.00pm (AEDT) on Business Days during the offer period for the Rights Offering.

Ends

This release was authorized by the COO and CFO, Brian Lane.

For more information, please contact:

Company	Investor and media relations
Brian Lane COO and CFO, Vioneering Technologies, Inc. Email: blane@vtivision.com	Haley Chartres H^CK Tel: +61 423 139 163 Email: haley@hck.digital

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1-Day Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit www.vtivision.com or call +1 844-884-5367, ext. 104.

Foreign ownership restrictions

VTI's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.